CorMedix Inc. (CRMD): Cost of Revenue
$22.09M
Year ended 2025-12-31
n/m
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $22.09M | +628.0% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $3.03M | n/a | 2026-03-05, From 2024-01-01 |
| No annual figure between 2022-12-31 and 2024-12-31. | |||
| 2022-12-31 | $3.7K | -97.5% | 2024-03-12, From 2022-01-01 |
| 2021-12-31 | $148.9K | -27.3% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $204.8K | -45.1% | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | $373.2K | -5.9% | 2021-03-30, From 2019-01-01 |
| 2018-12-31 | $396.8K | +245.1% | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | $115.0K | -68.6% | 2019-05-29, From 2017-01-01 |
| 2016-12-31 | $366.7K | n/c | 2018-03-19, From 2016-01-01 |
| 2015-12-31 | -$318.7K | n/m | 2017-03-16, From 2015-01-01 |
| 2014-12-31 | -$445.8K | n/m | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | -$201.6K | n/a | 2015-03-12, From 2013-01-01 |
| 2012-12-31 | $0 | n/a | 2014-03-31, From 2012-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| CorMedix Inc. (CRMD) | 2025-12-31 | $22.09M | +628.0% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $100.07M | +19.2% |
| MannKind Corp (MNKD) | 2025-12-31 | $26.80M | +53.8% |
| Harrow, Inc. (HROW) | 2025-12-31 | $67.93M | +38.0% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $36.70M | +91.8% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $113.25M | +50.1% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $124.03M | -11.8% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $39.54M | -21.8% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $39.46M | -37.5% |
Compare CRMD, EOLS, MNKD, HROW side by side · Screen every company in Pharmaceutical Preparations ↗